These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 15037147)

  • 1. Contrast nephrotoxicity and iso-osmolar contrast agents: implications of nephric.
    Morcos SK
    Clin Radiol; 2004 Mar; 59(3):297. PubMed ID: 15037147
    [No Abstract]   [Full Text] [Related]  

  • 2. Contrast-induced acute kidney injury in patients with renal dysfunction undergoing a coronary procedure and receiving non-ionic low-osmolar versus iso-osmolar contrast media.
    Alexopoulos E; Spargias K; Kyrzopoulos S; Manginas A; Pavlides G; Voudris V; Lerakis S; McLean DS; Cokkinos DV
    Am J Med Sci; 2010 Jan; 339(1):25-30. PubMed ID: 19996728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ureteric obstruction and intravascular administration of contrast media: is there a risk?
    Morcos SK
    Br J Radiol; 2003 Aug; 76(908):564-5. PubMed ID: 12893700
    [No Abstract]   [Full Text] [Related]  

  • 4. Low-osmolar and iso-osmolar contrast media in contrast-induced nephropathy.
    Savazzi G; Detrenis S; Meschi M; Musini S
    Am J Kidney Dis; 2005 Feb; 45(2):435; author reply 435. PubMed ID: 15685526
    [No Abstract]   [Full Text] [Related]  

  • 5. For patients with renal insufficiency, do low-osmolar iodinated contrast agents lessen the risk of nephrotoxicity, compared with high-osmolar agents?
    Hopper KD
    AJR Am J Roentgenol; 1997 Jun; 168(6):1615. PubMed ID: 9168738
    [No Abstract]   [Full Text] [Related]  

  • 6. [Guidelines for administering gadolinium-based contrast agents to patients with renal dysfunction--second edition].
    Hosoya T; Okada H; Horio M; Ohno I; Tamura S; Sugimoto H; Tsushima Y; Hayashi H; Fukuda K; Korogi Y; Yoshifumi N
    Nihon Jinzo Gakkai Shi; 2009; 51(7):839-42. PubMed ID: 19928554
    [No Abstract]   [Full Text] [Related]  

  • 7. [Are contrast agents containing gadolinium only counter-indicated for dialysis patients?].
    Witzke O
    Radiologe; 2008 Jan; 48(1):71; author reply 71. PubMed ID: 18043903
    [No Abstract]   [Full Text] [Related]  

  • 8. Contrast-induced nephropathy: are there differences between low osmolar and iso-osmolar iodinated contrast media?
    Morcos SK
    Clin Radiol; 2009 May; 64(5):468-72. PubMed ID: 19348841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent clinical trials of iodixanol.
    Erdogan A; Davidson CJ
    Rev Cardiovasc Med; 2003; 4 Suppl 5():S43-50. PubMed ID: 14668709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephrogenic systemic fibrosis: recommendations for gadolinium-based contrast use in patients with kidney disease.
    Perazella MA; Reilly RF
    Semin Dial; 2008; 21(2):171-3. PubMed ID: 18226005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: contrast-induced nephropathy: are there differences between low osmolar and iso-osmolar iodinated contrast media?
    Downes MO; Nicholson A
    Clin Radiol; 2010 Apr; 65(4):343-4; author reply 344-5. PubMed ID: 20338404
    [No Abstract]   [Full Text] [Related]  

  • 12. Nephrotoxicity and the role of contrast media.
    Aspelin P
    Radiat Med; 2004; 22(6):377-8. PubMed ID: 15648451
    [No Abstract]   [Full Text] [Related]  

  • 13. Nephrotoxicity related to contrast media.
    Berg KJ
    Scand J Urol Nephrol; 2000 Oct; 34(5):317-22. PubMed ID: 11186471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low osmolar contrast agents and nephrotoxicity.
    Evans JR; Shankel SW; Cutler RE
    Ann Intern Med; 1987 Jul; 107(1):116. PubMed ID: 3592430
    [No Abstract]   [Full Text] [Related]  

  • 15. Nephrogenic systemic fibrosis and gadolinium-based contrast: what's a nephrologist to do?
    Perazella MA
    Semin Dial; 2008; 21(2):121-2. PubMed ID: 18248521
    [No Abstract]   [Full Text] [Related]  

  • 16. Gadolinium contrast media for DSA in azotemia: are they really safer than iodinated agents?
    Nyman U; Elmståhl B; Leander P; Nilsson M; Golman K; Almén T
    Acad Radiol; 2002 Aug; 9 Suppl 2():S528-30. PubMed ID: 12188329
    [No Abstract]   [Full Text] [Related]  

  • 17. Contrast medium-induced nephrotoxicity.
    Drescher P; Madsen PO
    AJR Am J Roentgenol; 1998 Feb; 170(2):508-9. PubMed ID: 9456977
    [No Abstract]   [Full Text] [Related]  

  • 18. Aspects of contrast media nephrotoxicity.
    Morcos SK; Epstein FH; Haylor J; Dobrota M
    Eur J Radiol; 1996 Nov; 23(3):178-84. PubMed ID: 9003921
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety of gadolinium during pregnancy.
    Garcia-Bournissen F; Shrim A; Koren G
    Can Fam Physician; 2006 Mar; 52(3):309-10. PubMed ID: 16572573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular gadolinium-based contrast media: an overview.
    Bellin MF; Van Der Molen AJ
    Eur J Radiol; 2008 May; 66(2):160-7. PubMed ID: 18358659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.